Navigation Links
Surveyed U.S. and European Neurologists Agree that a Therapy's Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
Date:3/20/2013

BURLINGTON, Mass., March 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European neurologists agree that a therapy's effect on physical disability is the most influential attribute when making prescribing decisions for secondary-progressive multiple sclerosis (SP-MS)*. These same neurologists cite a therapy's effect on quality of life as the second-most important attribute, ahead of an effect on relapses, imaging metrics and other functional domains.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

Current management of SP-MS relies on the use of mainline disease-modifying therapies (which include interferon-betas and Teva's Copaxone), most of which are approved broadly for the treatment of relapsing forms of MS. This category encompasses relapsing-remitting MS (RR-MS) and SP-MS patients who continue to experience relapses. Interviewed thought leaders suggest that, based on data in RR-MS, Genzyme/Sanofi/Bayer HealthCare's Lemtrada may offer advantages over sales-leading Copaxone on measures of physical disability—potentially translating into clinical benefits for SP-MS patients. 

"The neurologists we surveyed indicate that an improved effect on physical disability is one of the greatest unmet needs in SP-MS," said Decision Resources Analyst Georgiana L. Kuhlmann , S.M. "Drawing on clinical data from RR-MS trials, interviewed thought leaders indicate that Lemtrada has demonstrated the potential to partially fulfill this unmet need."

According to the DecisionBase 2013 report entitled On What Attributes Will Neurologists and Payers Differentiate Novel Therapies for Secondary-Pro
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
2. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
3. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
4. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
5. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
6. Mylan Launches Generic Lipitor® in Five European Countries
7. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
8. Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress
9. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
10. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
11. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 2014   Long Beach dentist , Dr. Rassouli, is ... gold standard in tooth replacement because they offer the closest ... to restore and preserve smiles and improve overall dental health. ... tooth or as a part of a smile makeover or ... of a smile. The loss of a tooth ...
(Date:11/22/2014)...  Particle Sciences, Inc (PSI), the leading CDMO ... a new innovative vaginal ring for Ladee Pharma ... of Exeltis Pharmaceuticals.  According to Bruce Frank ... Sciences, "This vaginal ring was developed for LPRI ... modeling expertise.  We are thrilled it is now ...
(Date:11/21/2014)... Nov. 21, 2014  Alere Inc. (NYSE: ... has appointed Juliet Cunningham as Vice President, ... be responsible for driving communications with the investment community. ... series of changes to increase shareholder value, it is ... said Namal Nawana, Chief Executive Officer. "We are delighted ...
Breaking Medicine Technology:Long Beach Dentist, Dr. Rassouli, is Now Offering Dental Implants 2Particle Sciences' Clinical Trial Supplies Group Manufactures Innovative Vaginal Ring 2Alere Appoints Juliet Cunningham to Lead Investor Relations 2
... November 24, 2011 ProQares - ... services for protective equipment against chemical hazards - ... Screening, Inc. (RPS®) - a leading developer of ... countries throughout the European and Asia Pacific regions. ...
... Nov. 23, 2011 The U.S. Food and Drug ... use as needed to treat insomnia characterized by middle-of-the-night ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) This ... drug for this condition. Intermezzo should only be used ...
Cached Medicine Technology:Leading Chemical Weapons Preparedness Companies Announce Partnership to Deploy Break-through Diagnostic Test Internationally 2FDA Approves First Insomnia Drug for Middle-of-the-Night Waking Followed By Difficulty Returning to Sleep 2
(Date:11/24/2014)... CO, and Philadelphia, PA (PRWEB) November 24, 2014 ... provider of care coordination and disease management services ... has chosen to implement Essette’s Medical Management software ... new Essette SaaS platform in a program to ... Essette suite includes Population Health Management, Care Management, ...
(Date:11/23/2014)... 2014 The clinical trial report, ... data on the Aspergillosis clinical trial scenario. This ... the clinical trials on Aspergillosis. It includes an ... status as per the site of trial conduction ... coverage of disease clinical trials by their phase, ...
(Date:11/23/2014)... Tbdress.com has recently announced that ... Nov. 28, 2014. The special offer will provide ladies many ... one of the world’s largest women’s dresses retailers, and its ... can enjoy great discounts on that day: Everything at Tbdress.com ... (for orders above $89). , People can use the following ...
(Date:11/23/2014)... (HealthDay News) -- The holidays can be a challenge ... can trigger major meltdowns, an expert says. "Holidays ... circumstances, but when you have children with special needs, ... therapy professor at University of the Sciences in Philadelphia, ... to let your hosts or visitors know what special ...
(Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers are ... announced its new collection of power suppliers. Additionally, it ... power suppliers. All the new models come with big ... until Dec. 20, 2014. , SWAccessControl.com has thousands of ... it for a long time. It is very wise ...
Breaking Medicine News(10 mins):Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2
... Dodge to Give Away Custom Dodge Vehicle After ... the best-selling men,s,magazine on newsstands, announced today that ... Apprentice" winner, Bill,Rancic will host the Men,s Health ... Chicago native Rancic is currently co-host of NBC,s,"In ...
... AARP Andrus Award Recognizes Outstanding Service, LAKESIDE, ... has been selected by AARP, the nonprofit membership,organization ... 2007 AARP,Andrus Award for Community Service, the Association,s ... This award symbolizes that,individuals have the power and ...
... FL(October 9, 2007)Accentia Biopharmaceuticals announces that it met ... September 26, 2007 for a scheduled pre-Investigational New ... has indicated its support for Accentia to submit ... controlled, multi-center clinical trial of Revimmune, the companys ...
... and Standards,Development, Clear Method to Identify and ... legal analysis released,today by The George Washington University ... the Robert Wood Johnson Foundation (RWJF) affirms,the legality ... systems used,by health plan provider networks. Recent efforts ...
... Green Pet Products, an Iowa-based,manufacturer of all-natural ... development and introduction of a special sanitizing ... http://www.newscom.com/cgi-bin/prnh/20071009/CLTU089 ) Organic-based litters ... over this microbiological content and its,adverse effects ...
... is important for many clinical trials and essential for ... was the message delivered today by the European Medical ... councils across Europe based at the European Science Foundation ... rare diseases and about to launch a review of ...
Cached Medicine News:Health News:Entrepreneur and TV Personality Bill Rancic to Host Men's Health Chicago Urbanathlon on October 20, 2007 2Health News:Lakeside Resident Wins AARP Community Service Award 2Health News:Accentia announces investigational new drug application for Revimmune for refractory MS 2Health News:Accentia announces investigational new drug application for Revimmune for refractory MS 3Health News:New Analysis Underscores Legality of Physician Ranking and Public Reporting Systems When Used by Health Insurers to Improve Health Care Quality 2Health News:New Analysis Underscores Legality of Physician Ranking and Public Reporting Systems When Used by Health Insurers to Improve Health Care Quality 3Health News:New Analysis Underscores Legality of Physician Ranking and Public Reporting Systems When Used by Health Insurers to Improve Health Care Quality 4Health News:Green Pet Products Introduces a New, Innovative Process to the Small Animal and Bird Litter/Bedding Category 2Health News:Paving the way for future pan-European clinical trials 2Health News:Paving the way for future pan-European clinical trials 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: